Spots Global Cancer Trial Database for epidermal growth factor receptor (egfr)
Every month we try and update this database with for epidermal growth factor receptor (egfr) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Microdose Evaluation Study of ABY-029 in Recurrent Glioma | NCT02901925 | Glioma | ABY-029 | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC | NCT03611738 | Non-small Cell ... Lung Cancer Non-small Cell ... Non-small Cell ... Stage IV Non-sm... EGFR Negative N... | Ceritinib Docetaxel | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC) | NCT01999985 | Lung Cancer Non-small Cell ... | Dasatinib - 1A Afatinib - 1A Dasatinib - 1B Afatinib - 1B | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations | NCT05801029 | Non-Small Cell ... | Osimertinib Amivantamab | 18 Years - 130 Years | AstraZeneca | |
| A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations | NCT05801029 | Non-Small Cell ... | Osimertinib Amivantamab | 18 Years - 130 Years | AstraZeneca | |
| Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma | NCT01941849 | Phaeochromocyto... Paraganglioma | Vandetanib 131I-mIBG | 18 Years - | University College, London | |
| Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma | NCT01941849 | Phaeochromocyto... Paraganglioma | Vandetanib 131I-mIBG | 18 Years - | University College, London | |
| A Microdose Evaluation Study of ABY-029 in Recurrent Glioma | NCT02901925 | Glioma | ABY-029 | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases | NCT06319950 | Lung Cancer, No... | Furmonertinib Osimertinib | 18 Years - 80 Years | Taizhou Hospital | |
| A Microdose Evaluation Study of ABY-029 in Primary Sarcoma | NCT03154411 | Primary Soft-ti... | ABY-029 | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC | NCT03611738 | Non-small Cell ... Lung Cancer Non-small Cell ... Non-small Cell ... Stage IV Non-sm... EGFR Negative N... | Ceritinib Docetaxel | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Phase I Dasatinib/Erlotinib in Recurrent Non-small Cell Lung Cancer (NSCLC) | NCT00444015 | Non-Small-Cell ... | Erlotinib in co... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma | NCT04547777 | Glioma, Maligna... | D2C7-IT 2141-V11 | 18 Years - | Duke University | |
| A Microdose Evaluation Study of ABY-029 in Recurrent Glioma | NCT02901925 | Glioma | ABY-029 | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation | NCT01859026 | Lung Cancer Non-Small Cell ... | MEK162 Erlotinib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC | NCT03611738 | Non-small Cell ... Lung Cancer Non-small Cell ... Non-small Cell ... Stage IV Non-sm... EGFR Negative N... | Ceritinib Docetaxel | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin | NCT00981058 | Non Small Cell ... | Necitumumab Gemcitabine Cisplatin | 18 Years - | Eli Lilly and Company | |
| Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC) | NCT01999985 | Lung Cancer Non-small Cell ... | Dasatinib - 1A Afatinib - 1A Dasatinib - 1B Afatinib - 1B | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers | NCT05176665 | Neoplasms Neoplasm Metast... Metastatic Gast... | EMB-01 | 18 Years - | Shanghai EpimAb Biotherapeutics Co., Ltd. | |
| Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma | NCT04547777 | Glioma, Maligna... | D2C7-IT 2141-V11 | 18 Years - | Duke University | |
| First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin | NCT00982111 | Non Small Cell ... | Pemetrexed Cisplatin Necitumumab | 18 Years - | Eli Lilly and Company | |
| First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin | NCT00981058 | Non Small Cell ... | Necitumumab Gemcitabine Cisplatin | 18 Years - | Eli Lilly and Company | |
| Study of IMC-11F8 in Participants With Advanced Solid Tumors | NCT01088464 | Neoplasms | IMC-11F8 IMC-11F8 IMC-11F8 | 20 Years - | Eli Lilly and Company | |
| Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) | NCT06074588 | Non-small Cell ... | Sacituzumab tir... Docetaxel Pemetrexed | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer | NCT02789345 | Non-small Cell ... | Ramucirumab Necitumumab Osimertinib | 18 Years - | Eli Lilly and Company | |
| Study of IMC-11F8 in Participants With Advanced Solid Tumors | NCT01088464 | Neoplasms | IMC-11F8 IMC-11F8 IMC-11F8 | 20 Years - | Eli Lilly and Company | |
| High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases | NCT06319950 | Lung Cancer, No... | Furmonertinib Osimertinib | 18 Years - 80 Years | Taizhou Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
